Merck Agrees to License Its Antiviral Pill to Medicines Patent Pool

Merck has struck a licensing pact with the Medicines Patent Pool (MPP), a United Nations-supported public health organization serving the developing world, to expand access to its experimental COVID-19 antiviral pill, molnupiravir, co-developed with Ridgeback Biotherapeutics.
Source: Drug Industry Daily